Jason T K Hwang1, Ying R Gu2, Mi Shen2, Ranju Ralhan3, Paul G Walfish4, Kenneth P H Pritzker5, David Mock6. 1. Proteocyte Diagnostics Inc., Toronto, Ontario, Canada. Electronic address: Jhwang@proteocyte.com. 2. Proteocyte Diagnostics Inc., Toronto, Ontario, Canada. 3. Proteocyte Diagnostics Inc., Toronto, Ontario, Canada; Alex and Simona Shnaider Research Laboratory in Molecular Oncology, Toronto, Ontario, Canada; Otolaryngology-Head and Neck Surgery, Sonshine Family Centre for Head and Neck Diseases, Toronto, Ontario, Canada; Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada. 4. Proteocyte Diagnostics Inc., Toronto, Ontario, Canada; Alex and Simona Shnaider Research Laboratory in Molecular Oncology, Toronto, Ontario, Canada; Otolaryngology-Head and Neck Surgery, Sonshine Family Centre for Head and Neck Diseases, Toronto, Ontario, Canada; Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada; Medicine, Endocrine Division, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada. 5. Proteocyte Diagnostics Inc., Toronto, Ontario, Canada; Laboratory Medicine and Pathobiology: Surgery, University of Toronto, Toronto, Ontario, Canada; Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada. 6. Proteocyte Diagnostics Inc., Toronto, Ontario, Canada; Oral Pathology/Oral Medicine, Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada.
Abstract
OBJECTIVE: The standard of care for premalignant lesion risk assessment is dysplasia grading by histopathology. With significant overlap between dysplasia grades and high inter- and intraobserver variations, histopathology dysplasia grading alone is not a useful prognostic tool. Our aim is to investigate whether a method for quantitatively assessing S100A7, a prognostic biomarker, using image analysis can better predict clinical outcome in cases with oral dysplasia. STUDY DESIGN: Using the Visiopharm image analysis system, we analyzed a cohort of 150 oral biopsy samples to build and test Straticyte, a model for individualized assessment of the 5-year risk of progression of oral precancerous lesions to invasive squamous cell carcinomas. RESULTS: Straticyte classified lesions more accurately than histopathological dysplasia grading for risk to progression to cancer over the following 5 years. The sensitivity of low-risk versus intermediate- and high-risk Straticyte groups was 95% compared to 75% for mild versus moderate and severe dysplasia. Furthermore, the negative predictive value for low-risk versus intermediate- and high-risk Straticyte groups was 78% compared to 59% for mild versus moderate and severe dysplasia. CONCLUSION: By quantitatively assessing S100A7, Straticyte better defines the risk for developing oral squamous cell carcinoma than histopathological dysplasia grading alone.
OBJECTIVE: The standard of care for premalignant lesion risk assessment is dysplasia grading by histopathology. With significant overlap between dysplasia grades and high inter- and intraobserver variations, histopathology dysplasia grading alone is not a useful prognostic tool. Our aim is to investigate whether a method for quantitatively assessing S100A7, a prognostic biomarker, using image analysis can better predict clinical outcome in cases with oral dysplasia. STUDY DESIGN: Using the Visiopharm image analysis system, we analyzed a cohort of 150 oral biopsy samples to build and test Straticyte, a model for individualized assessment of the 5-year risk of progression of oral precancerous lesions to invasive squamous cell carcinomas. RESULTS: Straticyte classified lesions more accurately than histopathological dysplasia grading for risk to progression to cancer over the following 5 years. The sensitivity of low-risk versus intermediate- and high-risk Straticyte groups was 95% compared to 75% for mild versus moderate and severe dysplasia. Furthermore, the negative predictive value for low-risk versus intermediate- and high-risk Straticyte groups was 78% compared to 59% for mild versus moderate and severe dysplasia. CONCLUSION: By quantitatively assessing S100A7, Straticyte better defines the risk for developing oral squamous cell carcinoma than histopathological dysplasia grading alone.
Authors: Paola Fernandes Pansini; Isabella Bittencourt do Valle; Thabata Coeli Dias Damasceno; Priscila Marinho de Abreu; Anna Clara Gregório Có; Rossana Verónica Mendoza López; Jeferson Lenzi; Ricardo Mai Rocha; Evandro Duccini Souza; Maria Paula Curado; Hisham Mehanna; Paul Nankivell; José Roberto Vasconcelos de Podestá; Sandra Ventorin von Zeidler Journal: Head Neck Pathol Date: 2021-04-11